Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.
Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.
Pieris has a diverse pipeline of Anticalin Therapeutics for a number of different indications and has active, multi-program R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila and Stelis Biopharma.
Pieris, founded in 2001, was funded by premier biotechnology-focused venture capital firms including OrbiMed Advisors as its lead investor as well as Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.
Pieris has become a publicly traded company on December 18, 2014 (NASDAQ:PIRS).